ATLAS All-in-One
Composition, choice of forms and safety profile
Information for doctors, pharmacists and therapists
- 35components
- 4capsules per daily serving
- 50%highest share of an upper level (UL)
- 23individually verified sources
- 120 capsules, 95 g
- Daily serving 4 capsules with a sip of water
- Made in Lengau, Upper Austria
- Formula as at 8 July 2026
- Document as at 19 August 2026
- Dr med univ Kurosch Borhanian
Specialist in general and visceral surgery
ATLAS All-in-One is a food supplement, not a medicinal product. This document is addressed to doctors, pharmacists and members of therapeutic professions. It places composition, the nutrient compounds used and amounts in a professional context and is not advertising directed at consumers. It does not replace individual advice.
§ 0 The composition
All figures per daily serving, taken from the printed label.
| Component | Chemical form | Amount | % NRV |
|---|---|---|---|
| Thiamine (B1) | Thiamine mononitrate | 2.6 mg | 236 |
| Riboflavin (B2) | Riboflavin 5′-phosphate sodium | 2.6 mg | 186 |
| Niacin (B3) | Nicotinamide | 16 mg NE | 100 |
| Pantothenic acid | Calcium D-pantothenate | 12 mg | 200 |
| Vitamin B6 | Pyridoxal 5'-phosphate | 2.3 mg | 164 |
| Biotin | D-biotin | 104 µg | 208 |
| Folate | (6S)-5-methyltetrahydrofolic acid glucosamine salt | 400 µg | 200 |
| Vitamin B12 | Methylcobalamin | 75 µg | 3.000 |
| Vitamin C | Calcium L-ascorbate141 mgL-ascorbyl 6-palmitate20 mg | 161 mg | 201 |
| Vitamin D | Cholecalciferol | 50 µg2,000 IU | 1.000 |
| Vitamin K | Menaquinone (K2) | 150 µg | 200 |
| Vitamin E | Mixed tocopherols1.7 mg α-TED-alpha-tocopheryl acetate14 mg | 15.7 mgα-TE | 131 |
| Magnesium | Magnesium malate96 mgMagnesium bisglycinate complex (MagChel®)80 mg | 176 mg | 47 |
| Zinc | Zinc bisglycinate | 10 mg | 100 |
| Manganese | Manganese gluconate | 2 mg | 100 |
| Selenium | Sodium selenite | 100 µg | 182 |
| Chromium | Chromium(III) chloride | 50 µg | 125 |
| Molybdenum | Sodium molybdate | 101 µg | 202 |
| Component | Form or origin | Amount |
|---|---|---|
| Nicotinamide riboside | Nicotinamide riboside chloride | 300 mg |
| Coenzyme Q10 | Coenzyme Q10 | 150 mg |
| trans-Resveratrol | trans-Resveratrol | 150 mg |
| Ashwagandha | Winter cherry extractof which 5 mg withanolides | 90 mg |
| Grape seed | Extractof which 71 mg proanthocyanidins, 37.5 mg OPC | 75 mg |
| Green tea | Extractof which 71 mg polyphenols, 33 mg EGCG | 75 mg |
| Acetyl-L-carnitine | Acetyl-L-carnitine hydrochloride | 64 mg |
| Alpha-lipoic acid | Alpha-lipoic acid | 60 mg |
| Rosehip | Extract | 60 mg |
| Hop flower | Extractof which 1.5 mg xanthohumol | 30 mg |
| Hericium | Extract, polysaccharides | 25 mg |
| Cordyceps | Cordyceps sinensis, extract, polysaccharides | 24 mg |
| Lutein | Marigold extract | 10 mg |
| Quercetin | Quercetin phospholipid powder | 10 mg |
| Astaxanthin | Haematococcus pluvialis, powder | 6 mg |
| Theobromine | Cocoa extract | 5 mg |
| Zeaxanthin | Marigold extract | 1.3 mg |
35 components. Capsule shell hydroxypropyl methylcellulose. Ashwagandha, Hericium and Cordyceps extract naturally contain sulphites. No iron, no iodine. Calcium is not declared as a nutrient; it occurs solely as a carrier salt in calcium L-ascorbate and calcium D-pantothenate.
§ 1 What the preparation is - and who it is not for
ATLAS All-in-One is a food supplement for daily intake over an extended period. It covers a broad basic requirement of vitamins and minerals and contains 17 further components alongside - coenzyme Q10, nicotinamide riboside, plant extracts, natural pigments (carotenoids).
It is not a therapy and not a substitute for targeted substitution. Anyone with a demonstrated deficiency needs a single preparation at the dose appropriate for it and monitoring of the course. A combination preparation can do neither: it doses for the basic requirement, not for a gap, and it cannot be titrated.
Who it is not intended for
- Pregnant and breastfeeding women and persons under 18
- Anyone consuming other products containing green tea on the same day
- Anyone taking medicines without that intake having been discussed. § 6 names the constellations in which this discussion is not a formality but matters in substance
And one limitation that is on no label: anyone who is young, eats a varied diet and is under no particular strain will be able to expect little from a preparation of this breadth. The underlying idea is to supplement an already sensible diet, not to replace it - recognisable from the amounts (§ 2).
§ 2 Why 35 components
The obvious criticism of a preparation of this breadth is that breadth takes the place of a decision: put everything in and you are probably skimping on the doses.
The objection holds for part of this product category. For ATLAS it describes how it came about the wrong way round.
The number was not a specification. What was specified were 2 goals that limit each other:
- As complete as possible. What is sensible and supported by sufficient literature should be in it.
- As simple as possible to take. One serving daily, tasteless, with no preparation.
35 is therefore not a chosen figure but the result of that balance. Choosing a number would have been the more arbitrary decision.
And a third specification that determines every single amount
The preparation is designed to be taken daily over years. That is a different dosing problem from a time-limited intervention. Anyone taking something over years does not need a study dose - they need an amount that supplements a normal diet and stays safe over time.
2 figures in the declaration show this principle:
- Magnesium: 176 mg, 47 % of the reference value - the only figure below 100 % in the table. It is not a technical limit; a higher amount would have been possible. It is the amount that supplements a balanced diet without replacing it.
- Vitamin D: 50 µg (2,000 IU) - above the D-A-CH estimate of 20 µg for adults with no endogenous synthesis, at half the tolerable upper level of 100 µg derived by the EFSA. Here too more would be possible; here too duration is the argument (§ 4).
A preparation in which every figure sits at the upper edge is dosed to impress, not for the long run.
What could make a component fail
2 questions decided every substance, and both could come out negative: is it sufficiently evidenced? And: can an amount that makes sense over the long run be fitted into the volume available? Where either answer was no, the substance is not in it - regardless of how well it would have looked on a label. § 4 names 4 such decisions.
§ 3 The choice of forms
In a combination preparation the choice of compound decides the outcome as much as the amount does. The overview below names, for each component, the compound used and the compound otherwise predominantly used in this product category.
What this overview deliberately does not do: it evaluates neither side. Statements about better absorption of a compound are health claims within the meaning of Regulation (EC) No 1924/2006; no such claim is authorised for bioavailability. What is named is therefore what the compound is chemically and how it differs. The judgement is left to the reader.
| Component | Used | Usual alternative | Chemical difference |
|---|---|---|---|
| Magnesium | Used Magnesium malate · magnesium bisglycinate complex | Usual alternative Magnesium oxide, carbonate | Chemical difference Malate is an organic compound; in the bisglycinate complex, the brand-name raw material MagChel® (MAGNESIA GmbH), magnesium is bound to 2 glycine molecules (1 : 2), and according to the ingredient list the complex also contains magnesium oxide |
| Folate | Used (6S)-5-methyltetrahydrofolic acid as glucosamine salt | Usual alternative Folic acid | Chemical difference The form that circulates in the blood. Folic acid is the synthetic precursor and is reduced enzymatically |
| Vitamin B12 | Used Methylcobalamin | Usual alternative Cyanocobalamin | Chemical difference One of the 2 cobalamin forms active in the body. Cyanocobalamin carries a cyanide group at the same position |
| Vitamin B6 | Used Pyridoxal 5'-phosphate | Usual alternative Pyridoxine hydrochloride | Chemical difference The phosphorylated coenzyme form |
| Riboflavin | Used Riboflavin 5′-phosphate sodium | Usual alternative Riboflavin | Chemical difference Likewise the phosphorylated form; water-soluble |
| Vitamin K | Used Menaquinone (K2) | Usual alternative Phylloquinone (K1) | Chemical difference A different molecule with a different side chain, not the same substance in another presentation |
| Vitamin E | Used Mixed tocopherols · D-alpha-tocopheryl acetate | Usual alternative dl-alpha-tocopheryl acetate | Chemical difference D-alpha is the natural stereoform; dl-alpha is a mixture of 8 stereoisomers |
| Vitamin C | Used Calcium L-ascorbate · L-ascorbyl 6-palmitate | Usual alternative Ascorbic acid | Chemical difference A salt and a fatty acid ester; neither is acidic |
| Zinc | Used Zinc bisglycinate | Usual alternative Zinc oxide, sulphate | Chemical difference Chelate of zinc and 2 glycine molecules |
| Selenium | Used Sodium selenite | Usual alternative Selenomethionine, selenium yeast | Chemical difference An inorganic selenium salt. Unlike selenomethionine it is not incorporated into body proteins in place of methionine |
| Chromium | Used Chromium(III) chloride | Usual alternative Chromium picolinate, nicotinate | Chemical difference Trivalent chromium as an inorganic salt - the oxidation state in which chromium occurs in foods |
| Acetyl-L-carnitine | Used Acetyl-L-carnitine hydrochloride | Usual alternative L-carnitine, L-carnitine tartrate | Chemical difference The acetylated form, stabilised as the hydrochloride |
| Quercetin | Used Quercetin phospholipid powder | Usual alternative Quercetin dihydrate | Chemical difference Formulated with sunflower lecithin |
| Astaxanthin | Used From the microalga (Haematococcus pluvialis) | Usual alternative Synthetic astaxanthin | Chemical difference Algal origin |
| Lutein · zeaxanthin | Used From marigold extract (Tagetes) | Usual alternative the same origin is usual | Chemical difference - |
The full assignment of all 35 components is in Annex A.
§ 4 What is not in it
4 omissions are decisions, not oversights.
An ingredients list is read by what is missing from it too.
Iron not included
Not included. Iron deficiency is common, a general need for iron is not - and substitution should be tied to a laboratory value and monitored, not to a preparation for daily use.
There is also tolerability. A meta-analysis of 43 randomised controlled trials with 6,831 adults found a doubling of gastrointestinal side effects for ferrous sulfate versus placebo (OR 2.32; 95 % CI 1.74-3.08).1 A Cochrane review of 67 studies with 8,506 women quantifies the individual symptoms and rates the evidence for them as high: hard stools and constipation RR 2.07 (1.35-3.17), loose stools RR 2.13 (1.10-4.11).2
In a preparation taken daily and without laboratory monitoring, iron is the component with the least favourable ratio of precision to tolerability.
Iodine not included
Not included. Where thyroid autonomy is present, additional iodine can trigger hyperthyroidism; iodine-induced thyroid dysfunction is described as a cause of thyrotoxicosis in its own right.3 A preparation for daily use also reaches those in whom autonomy is not known.
Calcium carrier salt only
Not declared as a nutrient. It occurs solely as a carrier salt in calcium L-ascorbate and calcium D-pantothenate. A dietary calcium deficiency is rare in this target group, and the amount that would make a contribution lies in the gram range - that is, outside what 4 capsules hold (§ 2).
Vitamin D: 50 µg (2,000 IU), no more
Included, but deliberately limited. The figure lies above the D-A-CH estimate of 20 µg (800 IU) for adolescents and adults in the absence of endogenous synthesis16 and at half the tolerable upper level of 100 µg (4,000 IU) derived by the EFSA.12
Higher daily doses cannot be justified in a preparation without measurement of levels, and still less for intake over years. The Endocrine Society guideline of 2024 advises against empirical supplementation above the reference intake in healthy adults under 75 (a conditional recommendation), and equally against routine 25(OH)D testing without indication.4
The figure chosen lies between the 2 marks - above the estimate, well below the upper level. That is the position that tolerates lasting intake without laboratory monitoring. Anyone who knows their level and needs more needs a single preparation - not a higher dose in a combination preparation.
§ 5 State of the evidence
Of 35 components, 18 carry a health claim authorised under European law. For the remaining 17 none is asserted - neither in this document nor on the pack nor in the sale.
The 18 are the vitamins and minerals. The 17 are everything else: coenzyme Q10, nicotinamide riboside, trans-resveratrol, acetyl-L-carnitine, alpha-lipoic acid, the carotenoids and the plant extracts.
“Not authorised” does not mean “not evidenced”
The distinction is not hair-splitting but the basis for judging this list.
An authorisation under Regulation (EC) No 1924/2006 is not an automatic result of the state of the research. It requires an application to have been filed, an applicant to fund it, and an assessment examining the causal relationship for exactly the composition applied for. A substance without an application stays without a claim - regardless of how much has been published on it.
The special case of the plant extracts
For botanical substances, assessment by the European Commission has been suspended since 2010. The corresponding claims sit on a so-called “on hold” list that was never decided.
The legal position has been settled since 2025, and settled in the strict direction. On 30 April 2025 the Court of Justice of the European Union ruled on a reference from the German Federal Court of Justice (C-386/23, Novel Nutriology GmbH v Verband Sozialer Wettbewerb e.V.). The operative part in its own words:
“Article 10(1) and (3) of Regulation (EC) No 1924/2006 […] must be interpreted, in the context of commercial advertising of a food supplement composed of ‘botanical substances’ […] as meaning that it is not permitted […] to use specific health claims relating to such substances […] or to make reference to the general, non-specific benefits of such a substance for overall good health and health-related well-being, until the European Commission has completed its examination […] unless the use of such claims is permitted under Article 28(6) of that regulation.”5
The operative part covers Article 10(3) as well - so not only the specific health claim but also the vague reference to “well-being”. The transitional rule in Article 28(6) applies only where an application was filed before 19 January 2008; in the original case the deadline had been missed.
For ashwagandha, Cordyceps, Hericium, hops, green tea, grape seed and rosehip the position is therefore without qualification: no claim, in any formulation. In this preparation they are stated with amount, extract form and characterising constituent - and with nothing else.
What follows from that
For 17 of the 35 components this document makes no statement about any effect. It names what is in it, in which form and in what amount. The judgement of whether any of these substances makes sense at this amount stays with the reader - and the reader has the same literature available as the manufacturer.
§ 6 Safety
Distance from the upper levels, interactions, labelling.
The figures below come from the opinions of the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), each from the primary source with its DOI. Several were reassessed in 2023 and 2024 and lowered in the process.
2 kinds of figure that are not the same thing. A tolerable upper intake level (UL) is derived from a dose-response relationship. Where the data did not allow that, the EFSA instead gave a safe level of intake and expressly noted that its application is more limited, because the threshold above which risk rises is not defined.6
| Component | in ATLAS | Figure | Type | Share | Source |
|---|---|---|---|---|---|
| Vitamin E | in ATLAS 15.7 mg | Figure 300 mg | Type UL | 5 % | Source |
| Vitamin B6 | in ATLAS 2.3 mg | Figure 12 mg | Type UL | 19 % | Source |
| Manganese | in ATLAS 2 mg | Figure 8 mg | Type safe level of intake | 25 % | Source |
| Selenium | in ATLAS 100 µg | Figure 255 µg | Type UL | 39 % | Source |
| Molybdenum | in ATLAS 101 µg | Figure 600 µg | Type UL | 17 % | Source |
| Folate | in ATLAS 400 µg | Figure 1,000 µg | Type UL | 40 % | Source |
| Zinc | in ATLAS 10 mg | Figure 25 mg | Type UL | 40 % | Source |
| Vitamin D | in ATLAS 50 µg | Figure 100 µg | Type UL | 50 % | Source |
The highest figure in the table sits at half. That follows from the design for lasting intake (§ 2), not from chance in the formula.
For context: the UL for selenium rests on alopecia as the earliest observable effect, derived from the SELECT trial.10 The UL for vitamin D rests on persistent hypercalciuria.12 The UL for folate expressly applies to (6S)-5-methyltetrahydrofolic acid glucosamine salt as well - that is, exactly the form used here.11
8 of the 18 vitamins and minerals are listed here. The figures for zinc and molybdenum come from assessments by the Scientific Committee on Food of 2002 and 2000 and had not yet been revised in the course of the 2023/24 reassessment - which is why the year stands in the table.
For the remaining 10 - thiamine, riboflavin, niacin, pantothenic acid, biotin, vitamin B12, vitamin C, vitamin K, magnesium and chromium - there is no figure this document could name with a verified source. A figure without a verified source does not appear here.
On the iron section in § 4: in 2024 the EFSA was likewise unable to derive a UL for iron and instead gave a safe level of intake of 40 mg/day; the critical endpoint was black stools as an indication of large amounts of unabsorbed iron in the gut.13 The side effects described in § 4 occur at therapeutic substitution doses below that figure - the safety figure is no measure of tolerability.
Interactions that matter in substance
The warning “If you are taking medicines, the product should only be taken under medical supervision” is on every pack. These constellations make it concrete.
Vitamin E under anticoagulation - the EFSA expressly excludes this group. The critical effect on which the UL for vitamin E rests is impairment of blood clotting and an increased risk of bleeding with it. The opinion states that the upper levels do not apply to persons taking anticoagulants or platelet aggregation inhibitors (e.g. acetylsalicylic acid), nor to patients in secondary prevention of cardiovascular disease or with vitamin K malabsorption.7
This is the most important constellation in this section, because it overlaps with the next. The product contains vitamin E and vitamin K; both touch on coagulation, from opposite directions. Under ongoing anticoagulation, taking it should therefore not merely be mentioned but discussed.
Vitamin K and vitamin K antagonists. Menaquinone acts on the same metabolic pathway as phenprocoumon or warfarin. Under ongoing anticoagulation, a constant intake is the precondition for the adjustment to hold; newly started supplementation changes it. That is not a contraindication but a reason to tell the treating doctor.
Coenzyme Q10, coumarins and antihypertensives. The product contains 150 mg. The BfR considers clinically relevant interactions with coumarin-type anticoagulants and with blood pressure-lowering medicines not conclusively assessable, and advises these patients to seek medical advice above a daily dose of 100 mg.17 The constellation should therefore be discussed.
Vitamin K2 and coumarins. The product contains 150 µg menaquinone-7. Even 10 µg MK-7 daily lowered the INR to a clinically relevant degree in at least 40 % of subjects on acenocoumarol; the authors advise avoiding MK-7 during vitamin K antagonist therapy.18 Use should be discussed beforehand, with INR monitoring when starting and stopping.
Biotin and laboratory testing. The product contains 104 µg. Biotin can interfere with immunoassays based on biotin-streptavidin binding (TSH, fT3/fT4, troponin), upwards or downwards depending on the assay format.19 Patients should tell the laboratory before blood is drawn.
Ashwagandha, liver and thyroid. The product contains 90 mg extract with 5 mg withanolides. Rare cholestatic or mixed liver injury has been described after 2 to 12 weeks, at daily amounts of 450 to 1,350 mg according to the product labels, with liver values normalising within 1 to 5 months.20 Severe courses occurred in patients with pre-existing liver disease.21 600 mg root extract daily lowered TSH and raised T3 and T4 in subclinical hypothyroidism.22 Since 2024 the German Federal Institute for Risk Assessment has advised against ashwagandha products in general and names no safe intake;23 Denmark has not permitted ashwagandha in food supplements since 2020. In liver or thyroid disease, its use should be discussed beforehand.
Green tea extract. The product contains 33 mg EGCG. The warning not to consume it on the same day as other green tea products and not on an empty stomach is not the manufacturer being cautious but follows the European rules for green tea extracts containing EGCG. The same rules require the warning not to exceed a daily intake of 800 mg EGCG.
Ashwagandha. Not during pregnancy or breastfeeding - as declared. Where thyroid disease is present, taking it should be discussed.
Chromium alongside antidiabetic medicines. 50 µg are contained. There is no upper level for chromium that this document could name with a verified source - unlike for the 8 substances in the table above. The constellation should nevertheless be named.
Matters requiring declaration
Ashwagandha, Hericium and Cordyceps extract naturally contain sulphites. The product is not intended for pregnant or breastfeeding women or persons under 18 and should not be consumed on an empty stomach.
§ 7 Manufacturing and testing
Made in Lengau, Upper Austria. The plant is certified to an internationally recognised food safety standard (FSSC 22000). The Global Food Safety Initiative recognises it; it goes beyond the food safety required by law.
Amber glass instead of plastic. Light-sensitive components degrade under UV exposure; the glass holds it back. The desiccant sachet supplied belongs in the container, not in the bin - the product is moisture-sensitive. Use up within 6 months of opening.
Laboratory testing of every batch
Every batch is tested by an external laboratory. A batch is only sold once testing is complete. We publish the full, unedited test report for every batch on the Quality & Standards page, with the batch number printed on the container.
§ 8 Disclosure
This document comes from the manufacturer. Its author runs ATLAS Health as a sole proprietorship and has a commercial interest in the sale of the product described.
It contains no recommendation. It contains the composition, the compounds chosen, the reasoning behind the omissions, the distance from the applicable upper levels and the interactions to be considered before taking it. Where a statement could not be evidenced, it is not in here.
The judgement of whether this product makes sense for you or for the people in your care is not something this document can take off your hands - and it does not want to.
Q Sources
Each source below is documented with its identifier and date.
- Tolkien Z, Stecher L, Mander AP, Pereira DIA, Powell JJ. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One 2015;10(2):e0117383. PMID 25700159 · doi.org/10.1371/journal.pone.0117383
- Low MSY, Speedy J, Styles CE, De-Regil LM, Pasricha SR. Daily iron supplementation for improving anaemia, iron status and health in menstruating women. Cochrane Database Syst Rev 2016;4:CD009747. PMID 27087396 · doi.org/10.1002/14651858.CD009747.pub2
- De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet 2016;388(10047):906-918. PMID 27038492 · doi.org/10.1016/S0140-6736(16)00278-6 - names iodine-induced thyroid dysfunction expressly as a cause of thyrotoxicosis in its own right. As a more recent overall review: Chaker L, Cooper DS, Walsh JP, Peeters RP. Hyperthyroidism. Lancet 2024;403(10428):768-780. PMID 38278171 · doi.org/10.1016/S0140-6736(23)02016-0
- Demay MB, Pittas AG, Bikle DD, et al. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2024;109(8):1907-1947. PMID 38828931 · doi.org/10.1210/clinem/dgae290
- Court of Justice of the European Union, judgment of 30 April 2025, Case C-386/23 (Novel Nutriology GmbH v Verband Sozialer Wettbewerb e.V.), ECLI:EU:C:2025:304, on a reference from the German Federal Court of Justice.
- EFSA NDA Panel. Guidance for establishing and applying tolerable upper intake levels for vitamins and essential minerals. EFSA Journal 2024;22(11):e9052 · doi.org/10.2903/j.efsa.2024.9052
- EFSA NDA Panel (Turck D, Bohn T, Castenmiller J, et al.). Scientific opinion on the tolerable upper intake level for vitamin E. EFSA Journal 2024;22(8):e8953. PMID 39099617 · doi.org/10.2903/j.efsa.2024.8953
- EFSA NDA Panel. Scientific opinion on the tolerable upper intake level for vitamin B6. EFSA Journal 2023;21(5):e08006. PMID 37207271 · doi.org/10.2903/j.efsa.2023.8006 - UL 12 mg/day (previously 25), critical effect peripheral neuropathy.
- EFSA NDA Panel. Scientific opinion on the tolerable upper intake level for manganese. EFSA Journal 2023;21(12):e8413. PMID 38075631 · doi.org/10.2903/j.efsa.2023.8413 - no UL derivable, safe level of intake 8 mg/day.
- EFSA NDA Panel. Scientific opinion on the tolerable upper intake level for selenium. EFSA Journal 2023;21(1):e07704. PMID 36698500 · doi.org/10.2903/j.efsa.2023.7704 - UL 255 µg/day (previously 300), LOAEL 330 µg from the SELECT trial.
- EFSA NDA Panel. Scientific opinion on the tolerable upper intake level for folate. EFSA Journal 2023;21(11):e08353. PMID 37965303 · doi.org/10.2903/j.efsa.2023.8353
- EFSA NDA Panel. Scientific opinion on the tolerable upper intake level for vitamin D, including the derivation of a conversion factor for calcidiol monohydrate. EFSA Journal 2023;21(8):e08145. PMID 37560437 · doi.org/10.2903/j.efsa.2023.8145 - UL 100 µg/day, critical endpoint persistent hypercalciuria.
- EFSA NDA Panel. Scientific opinion on the tolerable upper intake level for iron. EFSA Journal 2024;22(6):e8819. PMID 38868106 · doi.org/10.2903/j.efsa.2024.8819 - no UL derivable, safe level of intake 40 mg/day.
- Scientific Committee on Food (SCF). Opinion on the tolerable upper intake level of zinc, adopted on 5 March 2003 - UL 25 mg/day for adults. Not yet revised in the course of the 2023/24 reassessment.
- Scientific Committee on Food (SCF). Opinion on the tolerable upper intake level of molybdenum, 2000 - UL 600 µg/day for adults, derived from 10 µg per kg of body weight at 60 kg (NOAEL 0.9 mg/kg from rat studies, uncertainty factor 100). Likewise not yet revised.
- German, Austrian and Swiss nutrition societies. D-A-CH reference values for nutrient intake, vitamin D, as at 2012 - estimate 20 µg (800 IU) per day for adolescents from 15 years and adults in the absence of endogenous synthesis.
- German Federal Institute for Risk Assessment (BfR). Coenzyme Q10: what is known about health risks - and what is not? Questions and answers of 10 November 2023, in German · bfr.bund.de/fragen-und-antworten/thema/coenzym-q10-was-ist-ueber-gesundheitliche-risiken-bekannt-und-was-nicht
- Theuwissen E, Teunissen KJ, Spronk HMH et al. Effect of low-dose supplements of menaquinone-7 (vitamin K2) on the stability of oral anticoagulant treatment: dose-response relationship in healthy volunteers. J Thromb Haemost 2013;11(6):1085-92 · PMID 23530987 · doi.org/10.1111/jth.12203
- Dasgupta A. Immunoassay design and biotin interference. Adv Clin Chem 2022;109:165-183 · PMID 35953126 · doi.org/10.1016/bs.acc.2022.03.005
- Björnsson HK, Björnsson ES, Avula B et al. Ashwagandha-induced liver injury: A case series from Iceland and the US Drug-Induced Liver Injury Network. Liver Int 2020;40(4):825-829 · PMID 31991029 · doi.org/10.1111/liv.14393
- Philips CA, Valsan A, Theruvath AH et al. Ashwagandha-induced liver injury - A case series from India and literature review. Hepatol Commun 2023;7(10) · PMID 37756041 · doi.org/10.1097/HC9.0000000000000270
- Sharma AK, Basu I, Singh S. Efficacy and Safety of Ashwagandha Root Extract in Subclinical Hypothyroid Patients: A Double-Blind, Randomized Placebo-Controlled Trial. J Altern Complement Med 2018;24(3):243-248 · PMID 28829155 · doi.org/10.1089/acm.2017.0183
- German Federal Institute for Risk Assessment (BfR). Ashwagandha: sleeping berry preparations with possible health risks. Communication No. 039/2024 of 10 September 2024 (in German) · bfr.bund.de/cm/343/ashwagandha-schlafbeeren-praeparate-mit-moeglichen-gesundheitsrisiken.pdf
All 23 sources have been retrieved individually and verified with PMID, DOI, ECLI, the panel decision or the authority's statement together with its date.
Food supplements are not a substitute for a balanced and varied diet and a healthy lifestyle. The recommended daily intake must not be exceeded. Keep out of the reach of children.
